418 results about "Lipid Body" patented technology

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

The invention relates to the technical field of cosmetics, and discloses an anti-inflammatory soothing cosmetic composition which comprises the following components in percentage by weight: 0.5%-4% of a barrier repairing component, 0.5%-3% of an immunoregulation component, 0.3%-2.5% of a nerve soothing component, 0.3%-3% of an anti-inflammatory plant compound, 1%-10% of a moisturizing soothing enhancer and the balance of auxiliary materials. According to the components, through a five-dimensional synergistic mechanism of barrier repair, immune tolerance, nerve desensitization, anti-inflammatory itching relieving, moisturizing and stability maintaining, anti-inflammatory relieving and barrier repair are remarkably enhanced; ceramide, rare ginsenoside, phytosterol ester and free fatty acid are introduced to synergistically construct a bionic liposome which is closer to the composition of human cuticle lipid, so that the transdermal absorption and stability are enhanced, and the repair efficiency is remarkably improved; the dipotassium glycyrrhizinate, the tamarix chinensis flower extract, the purslane extract, the dinoflaxanthine and the baicalin cooperate to quickly resist inflammation and relieve itching and strengthen barrier repair, so that the composition is suitable for highly sensitive skin.

The invention relates to a composite dissoluble microneedle gel patch mask and a preparation method thereof. Comprising the following steps: (1) preparing a lipid oil phase solution and a water phase solution; mixing the lipid oil phase solution with the water phase solution to obtain a liposome suspension; (2) preparing recombinant collagen hydrogel; (3) adding the tea polyphenol and the lipidosome suspension into the recombinant collagen hydrogel to obtain composite gel; and (4) injecting the composite gel into a mold, carrying out vacuum drying, and demolding to obtain the composite dissoluble microneedle gel patch mask. According to the composite dissoluble microneedle gel patch mask provided by the invention, the tea polyphenol, the plant exosome and the liposome carrier are integrated into the microneedle gel patch mask for the first time, the oxidation resistance is improved by utilizing the tea polyphenol, the inflammation resistance is improved by utilizing the plant exosome, the transdermal effect is enhanced by utilizing the liposome, the transdermal efficiency reaches 35.2-42.5 mu g / cm < 2 > / h, the medical beauty effect is obvious, and the application prospect is wide. The obvious advantages are realized in the aspects of safety, transdermal efficiency and repairing effect.

The invention relates to the technical field of genetic engineering, in particular to a recombinant vector, an expression plasmid, a recombinant schizochytrium limacinum mutant and a method for increasing the DHA content of microorganisms. The LIP1 gene for coding lipase in the microbial lipid droplet protein is knocked out through a homologous recombination technology, and the production of lipase in the microbial lipid droplet can be effectively inhibited, so that the hydrolysis process of triglyceride of polyunsaturated fatty acid stored in the lipid droplet to glycerol and free fatty acid in the later stage of microbial culture is blocked, and DHA is prevented from being lost from a TAG repository; experimental verification shows that in microorganisms represented by schizochytrium limacinum, the DHA content can be increased by 21.8% compared with that of a wild type, the yield and purity of DHA are increased, the stability of the microbial fermentation process is guaranteed, and application and popularization are facilitated.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The invention discloses a bifunctional fluorescent molecular probe, a preparation method thereof and application of the bifunctional fluorescent molecular probe in polarity detection of ONOO <-> and lipid droplets, and belongs to the technical field of polarity detection of ONOO <-> and lipid droplets. The problems that a fluorescent probe is only limited to detection of a single analyte, and targeted monitoring of lipid droplets in cells and simultaneous detection of endogenous ONOO <-> in the cells cannot be achieved are solved. According to the invention, a dual-response fluorescent molecular probe PTQ based on a triphenylamine group is prepared, and the PTQ shows dual response to a polar environment and dynamic change of ONOO <->. Test results show that the fluorescent probe shows high sensitivity (1.92 nM), stable fluorescence signals and high quantum yield (57.76%) in a low-polarity medium, also has excellent ONOO <-> selectivity, low detection limit (4.97 nM), low toxicity and excellent biological imaging ability, and realizes targeted monitoring of lipid droplets and detection of endogenous ONOO <-> in cells.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are formulations for oral delivery or administration of therapeutic nucleic acids. An oral formulation can include: a nucleic acid; at least one casein protein; and a chitosan. In some embodiments, the formulations are liposome-free formulations having no cationic lipids typically used as transfection reagents in conventional nucleic acid formulations for oral delivery. The formulations provided herein find use in treating a condition associated with inflammation and / or fibrosis, or a cardiometabolic disorder by oral administration.

The invention belongs to the technical field of skin care products, and discloses a quick-acting red-removing repair product which comprises the following components: water, caprylic / capric triglyceride, glycerol, sorbitol, phosphatidylcholine, 1, 3-propylene glycol, xanthan gum, eicosapentaenoic acid, docosahexaenoic acid, phytosphingosine, centella asiatica extract and tocopheryl acetate. A turmeric rhizome extract and 1, 2-hexanediol. Through mutual cooperation of the turmeric root extract and the centella asiatica extract, by taking enhancement of skin immune regulation and skin barrier functions as an action mechanism, on one hand, skin inflammatory response can be inhibited, and inflammation, microorganisms and bacteria can be effectively resisted, and on the other hand, skin barrier reconstruction can be promoted, wound healing can be promoted, and an ECM matrix can be protected; in addition, the eicosapentaenoic acid, the docosahexaenoic acid, the turmeric root extract, the phytosphingosine and the centella asiatica extract are wrapped by the nano-microcapsule liposome, so that the activity of the product can be ensured.

The invention relates to the technical field of pharmaceutical preparations, and particularly provides colon-targeted pH-responsive nano-liposome and application thereof in improving oral bioavailability of saponin. Aiming at the problems of gastric acid damage, small intestine metabolism inactivation and low colon absorption efficiency during oral delivery of saponin, a three-layer core-shell structure design is adopted, wherein an inner core is composed of a saponin-phospholipid crystal compound; the middle layer is a chitosan-PEG bimolecular layer, and pH response release is realized in a colon environment with pH of 7.4; and the outer layer is modified with a folic acid-PE conjugate to enhance colon cell targeted recognition. The uniform nanoparticles with the particle size of 80 + / -5 nm are prepared by combining a gradient pH drug loading method with a microfluidic focusing technology. According to the preparation, the saponin bioavailability (AUC0-12 reaches 43.31 h. Microgram / mL) is remarkably improved, and the colon targeting property (the cell uptake rate is 52.9%) is enhanced. The innovativeness is that the gastrointestinal segmented protection and accurate colon release are synergistically realized through a multi-layer functional design, and the solubilization-permeation paradox of the traditional delivery technology is broken through.

The invention discloses a calcium liposome for promoting bone health as well as a preparation method and application thereof. The calcium liposome is prepared from the following components in parts by weight: 3 to 7 parts of phospholipid composition, 0.1 to 0.35 part of phytosterol, 1 to 5 parts of insoluble calcium, 1 to 7.5 parts of protein and 0.1 to 1 part of modifier, wherein the phospholipid composition consists of egg yolk lecithin, phosphatidylinositol and distearoyl phosphatidylcholine, and the mass ratio of the egg yolk lecithin to the phosphatidylinositol to the distearoyl phosphatidylcholine is (8-12): (7-11): ( The specific phospholipid composition obtained through screening is combined with phytosterol to serve as a membrane material to wrap a compound of insoluble calcium and protein, so that the dispersity and the stability of the prepared calcium liposome are obviously improved, when the calcium liposome is applied to preparation of calcium soft capsules, the oil leakage phenomenon is obviously reduced, meanwhile, the absorption of an organism to calcium is also enhanced, and the bioavailability of the calcium soft capsules is improved. Particularly, the bone mineral density and the bone calcium content of an organism are obviously increased, healthy development of bones is promoted, and the difficulty and the pain point of insoluble calcium applied to the fields of functional foods, health care products, biological medicines and the like are effectively solved.

A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21:50 μg / ml to 300 μg / ml; (2) Poly I:C: 400 μg / mL to 3000 μg / mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention discloses a mannose modified liposome gel microsphere oral delivery system based on cations and application of the mannose modified liposome gel microsphere oral delivery system. The oral delivery system comprises a core layer and a wrapping layer, the core layer is mannose modified cationic liposome loaded with a mucous membrane adjuvant retinoic acid and an antigen, and the wrapping layer is sodium alginate gel vulcanized and modified by cysteine. The mannose modified cationic liposome is prepared by coupling mannose on the surface of the cationic liposome, and the cysteine modified sodium alginate gel is used for protecting antigens in the core layer from being eroded by gastric juice, enhancing the adhesiveness of a delivery system in the intestinal tract and prolonging the retention time of the delivery system in the intestinal tract; in addition, the R-MLip can be expanded and released under the environment that the pH of the intestinal tract is increased. The inside of the gel microsphere of the oral delivery system shows a regular net-shaped structure and has abundant holes and channels, and the oral delivery system shows a good prospect in the aspect of enhancing mucous membrane and systemic immunity and possibly becomes a potential substitute of a traditional attenuated live vaccine in the future.

The invention discloses a double-targeting probe and a preparation method and application thereof.The structure of the double-targeting probe is shown in the formula I. The double-targeting probe has the beneficial effects that SO2 can be monitored in the cell apoptosis process, the dynamic change of SO2 between mitochondria and lipid droplets in cells can be tracked, the core structure of the probe MLR is based on a coumarin part, and the core structure of the probe MLR can be used for detecting the apoptosis of the cells. The probe MLR is connected with a benzopyran cation structure specially designed for detecting SO2, SO2 generated in the death process of copper enables charges of a cation part in the probe MLR to be redistributed, a Michael addition reaction of SO2 and carbon-carbon double bonds is triggered, a fluorescence signal of the probe is changed, and the fluorescence signal is detected. The design of the probe provides a new tool for monitoring key biochemical changes in the copper death process, and is helpful for deeply understanding the molecular mechanism of copper death.

The invention relates to the technical field of traditional Chinese medicine extract preparation, and discloses taste-masking enteric-coated traditional Chinese medicine extract particles which comprise drug-loaded pellets and enteric-coated coatings coating the drug-loaded pellets. The invention relates to a drug-loaded pellet. The coating comprises 20-45 parts of pure powder of the traditional Chinese medicine extract and 5-10 parts of dextrin; according to the taste-masking enteric-coated traditional Chinese medicine extract particle and the preparation method thereof, a stable barrier is formed in gastric juice through a carboxymethyl chitosan-lipidosome copolymer coating, and the degradation rate of effective components is reduced to 1t from 40-60% of a traditional preparation; the pH-responsive coating ensures that the rapid release rate of the intestinal tract is as high as 90%, the bioavailability is improved by 2-3 times, the bitter taste is completely covered by the coating layer, and the coating layer can be mixed with food to feed pets; the prepared sustained-release dosage form prolongs the action time of the medicine, reduces the medication frequency, reduces the medication cost of pet owners, and improves pet welfare.

The invention discloses neutral homogeneous lycium barbarum polysaccharide as well as a preparation method and application thereof. Through systematic structure characterization, it is clarified for the first time that the polysaccharide NLBPE1 is atypical arabinogalactan with 1, 5-alpha-L-arabinose as a bridging unit, and the polysaccharide NLBPE1 has a uniform molecular weight and a definite branched chain topological structure. The NLBPE1 serving as an adjuvant and an antigen are jointly entrapped in various delivery systems (such as PLGA nanoparticles, lipidosome, hydrogel and the like) to form the vaccine composition, so that the immunogenicity of the vaccine can be remarkably improved, and the antigen-specific T cell response can be enhanced. The invention provides an application scheme of the polysaccharide as a vaccine adjuvant in tumor immunotherapy and tumor prevention, and particularly shows a remarkable synergistic anticancer effect when the polysaccharide is combined with an immune checkpoint inhibitor for use. The polysaccharide has a clear structure, good biocompatibility and remarkable immunological enhancement activity, and has a wide application prospect of tumor vaccine adjuvants.

The invention relates to an adipose-derived stem cell and exosome composition for mucosal inflammation and an application of the adipose-derived stem cell and exosome composition. The composition is composed of a hybrid nano-vesicle and a pulsatilla chinensis exosome compound in a mass ratio of 1: 1. The hybrid nanovesicles are prepared by fusing adipose-derived stem cell exosomes and lipidosome and modifying honey polysaccharide, and the pulsatilla chinensis exosome compound is loaded with interleukin 23 peptidomimetic, polyethylene glycol, black scale quantum dots and camptothecin. The composition has the functions of efficient anti-inflammation, immunoregulation, precise targeting and tissue repair, and meanwhile, the curative effect is enhanced through photo-thermal synergistic treatment. The preparation method comprises the steps of exosome extraction by a density gradient centrifugation method, liposome fusion and surface modification. The composition is suitable for treating mucosal inflammation such as inflammatory bowel disease and oral mucositis, has the advantages of high stability, good biocompatibility and the like, and provides a safe and effective novel treatment strategy for clinic.

The invention relates to a medicine for promoting skin injury repair and healing and a preparation method thereof, and belongs to the technical field of biological medicines.The medicine is prepared from a radix astragali preparata extract, lipidosome encapsulated panax notoginseng total saponin-RGD peptide, a honeysuckle flower-maca extract, an asiaticoside-hydroxypropyl-beta-cyclodextrin inclusion compound and dipotassium glycyrrhizinate; the radix astragali preparata extract is a product obtained by moistening radix astragali with honey, baking, extracting with deionized water, and adsorbing and purifying with a Sephadex G-15 column; the honeysuckle-maca extract is a product obtained by mixing dry honeysuckle powder and dry maca root powder according to the mass ratio of (3-5): (1-1.7), performing enzymolysis through cellulase, then performing common enzymolysis through ficin protease and papain, and performing adsorption and purification through an HPD722 macroporous adsorption resin column. All the components are compatible according to a specific proportion, so that the allergy and skin irritation risks are reduced, skin injury healing is reasonably promoted, and melanin deposition is effectively inhibited.

The invention relates to the technical field of functional drinks, in particular to a polypeptide synergistically strengthened cubilose collagen composite drink with a breast enlarging function and a preparation method of the polypeptide synergistically strengthened cubilose collagen composite drink. The drink contains fish collagen tripeptide, elastin peptide, cubilose peptide, pueraria mirifica isoflavone, red clover isoflavone and saffron crocus extract. A lipidosome delivery system is adopted to entrap polypeptide to form a nano-scale compound, nano-emulsion entraps phytoestrogen, and berry polyphenol and lipidosome-polypeptide form a stable ternary compound. Through the multi-way synergistic effect that phytoestrogen activates a mammary gland estrogen receptor, polypeptide promotes connective tissue collagen synthesis and cubilose peptide activates a growth factor signal, mammary gland development is remarkably promoted, the breast enlarging effect is achieved, the bioavailability reaches 85% or above, and the retention rate of active ingredients stored at normal temperature for 24 months is larger than 90%.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The present application relates to the technical field of vaccine production, in particular to a preparation method of a Sapindus saponin veterinary vaccine adjuvant, comprising: determining the limit concentration of Sapindus saponin with a hemolysis rate lower than 5% and preparing the vaccine adjuvant; determining the limit concentration of Sapindus saponin with a hemolysis rate lower than 5% against red blood cells by spectrophotometry; preparing the vaccine adjuvant by dialysis; and the vaccine adjuvant contains soybean lecithin and cholesterol in a weight ratio of 1:1. The present application first determines the safe use concentration of Sapindus saponin through a standard hemolysis experiment, ensures that the hemolysis rate of the prepared adjuvant meets the safety requirements, and avoids adverse reactions after injection; at the same time, the present application uses soybean lecithin and cholesterol as raw materials, and prepares the nano-liposome adjuvant embedding Sapindus saponin by dialysis, which does not require complex process operation, has low preparation cost, and has safety and practicability, and can effectively assist the vaccine to induce the body to produce stronger immune response and improve the protection effect of the vaccine.

The invention discloses a drug-loaded polymer, an STAT3 inhibitor composite nanoparticle, a preparation method of the STAT3 inhibitor composite nanoparticle and application of the STAT3 inhibitor composite nanoparticle in ophthalmic drugs. The STAT3 inhibitor composite nanoparticle comprises the drug-loaded polymer, an STAT3 inhibitor loaded on the drug-loaded polymer and thermosensitive lipidosome. The drug-loaded polymer is astaxanthin macromolecules, and the astaxanthin macromolecules are prepared by the following steps: in an inert atmosphere, performing condensation polymerization on astaxanthin and HPMDA, and then performing end capping reaction by using mPEG-OH. The compound is used for treating retinal neuron progressive death and ophthalmic diseases caused by axon loss of the retinal neuron progressive death, can show good ROS response and consumption performance, inhibits necrotic apoptosis, apoptosis and pyroptosis of cells, relieves cell death performance, and can show good drug slow release performance.

The present invention relates to a liposomal doxorubicin formulation, a method for producing a liposomal doxorubicin formulation and a liposomal doxorubicin formulation for use as a medicament, in particular for use in the treatment of cancer, uterine leiomyosarcoma and adnexal skin cancer.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.

The invention discloses saccharomyces cerevisiae engineering bacteria for efficiently synthesizing mogroside V on the basis of cytoplasm and lipid droplet double-cell area compartment and a construction method of the saccharomyces cerevisiae engineering bacteria. The construction method comprises the following steps: integrating truncated 3-hydroxy-3-methylglutaryl coenzyme A reductase tHMG1, pentenyl pyrophosphate isomerase IDI1, epoxy squalene cyclization enzyme ERG1, squalene synthetase ERG9, choline kinase ScCK, isopentenyl phosphokinase AtIPK, cucurbitadienol synthetase SgCDS, cyclic epoxy hydrolase SgEPH3, cytochrome P450 enzyme CYP87D18 and cytochrome P450 enzyme reductase AtCPR1 at the site of a saccharomyces cerevisiae genome GAL80; an ABC efflux protein PDR11, a glycosyl transferase UGTMG1, a sucrose synthase Susy and a glycosyl transferase SgUGT94-289-3 are integrated at a site Exg1 of a saccharomyces cerevisiae genome. The yield of mogroside V produced by shake flask fermentation of the saccharomyces cerevisiae engineering strain provided by the invention reaches 96.3 mg / L, so that mogroside V is efficiently synthesized from the beginning in the saccharomyces cerevisiae, and the saccharomyces cerevisiae engineering strain has important practical significance for promoting sustainable development of the mogroside industry.

The invention belongs to the technical field of biological medicines, and particularly relates to lipid nanoparticles as well as a preparation method and application thereof. The invention discloses a lipid nanoparticle. The material of the lipid nanoparticle comprises phospholipid and cholesterol. According to the invention, a lipid nano-carrier delivery system entrapped with apoptotic protein Bax is prepared through a microfluidic technology, and high encapsulation rate and stable delivery of protein drugs are realized. The nano-carrier delivery system capable of actively encapsulating the lipidosome realizes targeted delivery to senescent cells in vivo, so that senescent cell apoptosis is effectively induced, the proportion of senescent cells in tissues is reduced, and a new thought and means are provided for anti-aging treatment.

A kind of biotin or avidin labeled fat body and its preparation method, nano-carrier system. Biotin or avidin labeled fat body is prepared using specific amount of Bio-phospholipid or avidin-phospholipid, and the prepared fat body has the advantages of high purity, small particle size, good uniformity and high stability. Based on the biotin-avidin system, a nano-carrier system is constructed, which includes the biotin labeled fat body and the avidin modified target component. The system enables the fat body to carry any interested substance, such as viral recombinant protein, antibody and other protein drugs, nucleic acid drugs or small molecule drugs, etc., so as to be used for the treatment of diseases such as vaccines, cancer, infectious diseases and metabolic diseases.